Previous close | 141.34 |
Open | 141.10 |
Bid | 141.39 x 1000 |
Ask | 141.51 x 1100 |
Day's range | 140.31 - 141.80 |
52-week range | 121.00 - 144.98 |
Volume | 3824826 |
Avg. volume | 7,199,685 |
Market cap | 372B |
Beta (5Y Monthly) | 0.70 |
PE ratio (TTM) | 26.97 |
EPS (TTM) | 5.24 |
Earnings date | 22 Jan 2020 |
Forward dividend & yield | 3.80 (2.69%) |
Ex-dividend date | 2019-11-25 |
1y target est | 150.78 |
Stocks on Wall Street rose for the first time in four sessions Wednesday. Spurring them higher: President Donald Trump's remarks that trade talks with China were going "very well." Energy stocks led the broad-based rally, pushing the S&P 500 up more than half percent. Edward Jones investment strategist, Nela Richardson: SOUNDBITE: EDWARD JONES INVESTMENT STRATEGIST, NELA RICHARDSON (ENGLISH) SAYING: "Investors should expect more volatility. So more of the same next year. It doesn't wash away with an interim deal or a tweet or a change in rhetoric. What investors should look for is actual change in actions like a removal or roll back of the existing tariffs and no new tariffs." Shares of online travel agency Expedia among the biggest gainers on the S&P 500. Its CEO and finance head resigned after clashing with the board over strategy. Johnson & Johnson helped lift the Dow. The drug maker said recent tests showed its Baby Powder was free of asbestos. Earlier this year, the FDA reported trace amounts of the material in the product. Shares of Alphabet rallied. Google CEO Sundar Pichai will immediately take over as CEO of the parent company now that Larry Page and Sergey Brin are stepping aside.
Johnson & Johnson (JNJ) closed at $139.99 in the latest trading session, marking a -0.36% move from the prior day.
In an announcement, the House of Representatives Subcommittee on Economic and Consumer Policy said that its efforts to persuade Gorsky to testify included "repeated attempts to accommodate the company" over nearly a month. Democrat Raja Krishnamoorthi, chairman of the House panel investigating concerns about cancer-causing asbestos in cosmetic talc and powders, said he was disappointed Gorsky turned down the invitation. "Mr. Gorsky refuses to speak to the Subcommittee under oath, yet he has not refrained from making multiple public comments on the topic," Krishnamoorthi said in a statement.
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Here we discuss the ups and downs of J&J's (JNJ) stock this year.
Johnson & Johnson (JNJ) closed the most recent trading day at $139.38, moving +1.62% from the previous trading session.
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
A total of 155 tests were conducted by two different third-party labs using four different testing methods on samples from the same bottle tested by the FDA's contracted lab, the company said. The tests are the latest effort by J&J to prove the safety of its widely used consumer product after the test by the FDA prompted J&J to undertake a nationwide recall of one lot of Johnson's Baby Powder in October.
The “Asbestos in Talc Symposium,” sponsored by the Food and Drug Administration, was dominated by industry hands: Most of the 21 non-government participants had done work for talc companies, such as testing and serving as expert witnesses and consultants, symposium documents and other records show. Key sessions were led by witnesses for Johnson & Johnson in lawsuits alleging the company failed to warn customers that its Baby Powder was tainted with cancer-causing asbestos, the records show. Over the past 50 years, the FDA has relied upon - and often deferred to - industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
And according to data from Deutsche Bank Research, opioid-related deaths per million inhabitants has drastically increased in the U.S. compared to the other Organization for Economic Cooperation and Development (OECD) countries.
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Style Box ETF report for IWX
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Headlines moving the stock market in real time.
New report sets stage for greater mental health coverage.
Investing.com – President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower-priced prescription drugs for residents.
Oklahoma Attorney General Mike Hunter says he plans to appeal a judge’s order directing consumer products giant Johnson & Johnson to pay the state $465 million to help address the state’s opioid crisis. Hunter said Thursday the judge’s final order only covers one year of the state’s proposed abatement plan and that the actual costs to clean up the damage from the opioid crisis are much higher. Johnson & Johnson had asked the judge to consider reducing the final award based on pre-trial settlements totaling $355 million the state reached with other defendants in the case.
More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants. The suit is one of many J&J has faced in the United States, Canada and Europe over the implants, used to treat urinary incontinence and pelvic organ prolapse, in which organs shift from normal positions. J&J in October agreed to pay nearly $117 million to resolve claims in 41 U.S. states and the District of Columbia.
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.